ScreenerHero
CANTACantargia AB (publ)
STO · SE · Healthcare · Biotechnology · cantargia.com
2.088SEK+12.86%Mkt Cap: 49.65M $P/E: 3.12

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap49.65M $
Enterprise Value23.45M $
Revenue (TTM)30.35M $
Gross Profit30.35M $
Net Income (TTM)14.06M $
Revenue/Share0.1210 USD
Last Price2.088 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.12
P/E (Forward)-2.10
PEG—
EV/EBITDA1.46
EV/Revenue0.77
P/S1.75
P/B1.89
EPS (TTM)0.67
EPS (Forward)-0.94
52W Range
1.6808% of range6.590
52W High6.590 SEK
52W Low1.680 SEK
Profitability
Gross Margin100.00%
Oper. Margin-37654.74%
EBITDA Margin52.94%
Profit Margin46.41%
ROE55.28%
ROA49.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF14.36M $
CapEx (TTM)45.15K $
FCF Margin9.19%
FCF Yield5.62%
Net Debt-21.23M $
Net Debt/EBITDA-1.32
Balance Sheet
Debt/Equity—
Current Ratio7.03
Quick Ratio6.93
Book Value/Sh1.045 SEK
Cash/Share0.8790 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.250 SEK
Upside (mean)+295.1%
Target Range4.500 SEK – 12.00 SEK
SEK4.500+295.1% to meanSEK12.00
# Analysts2
Ownership
Shares Out.248.61M
Float239.92M
Insiders4.49%
Institutions26.63%
Technical
SMA 501.960 (+6.5%)
SMA 2003.564 (-41.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)732.52K
Avg Vol (10d)518.09K
Technical Indicators
RSI (14)47.5
MACD-0.0640
MACD Signal-0.0785
MACD Hist.+0.0144
BB Upper1.921 SEK
BB Middle1.824 SEK
BB Lower1.727 SEK
BB Width10.64%
ATR (14)0.1102 SEK
Vol Ratio (20d)8.79x